By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors WANG, Hsin-Ell; HSIA, Chien-Chung; WENG, Mao-Chi; LIN, Kun-Liang; KAO, Hao-Wen; CHEN, Chao-Cheng; CHI, Kwan-Hwa; TIEN, Der-Chi; LIN, Wuu-Jyh, filed on September 14, 2017, was made available online on May 10, 2018, according to news reporting origina
By a News Reporter-Staff News Editor at Clinical Trials Week Researchers detail new data in Autoimmune Diseases and Conditions- Multiple Sclerosis. According to news reporting out of Loerenskog, Norway, by NewsRx editors, research stated, "Disease modifying drugs help control the course of relapsing remitting multiple sclerosis; however, good adh
By a News Reporter-Staff News Editor at Pharma Business Week Amneal, a specialty pharmaceutical company, announced it has initiated a Phase 3 trial for IPX203. The IPX203 Phase 3 protocol has been agreed upon with the Food and Drug Administration in a Special Protocol Assessment. Keywords for this news article include: Antiparkinson Agents, Amnea
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "We are pleased by today's FDA approval of Lokelma as it enables us to help address a long-standing clinical need with a new medicine that offers rapid and sustained treatment for adults with hyperkalaemia. Steven Fishbane, MD, Profess
LONDON- British drug major AstraZeneca announced Monday that the US Food and Drug Administration or FDA has approved Lokelma, formerly ZS-9, for the treatment of adults with hyperkalaemia. The European Commission granted marketing authorisation for Lokelma in the European Union on March 22, 2018. Sean Bohen, Chief Medical Officer at AstraZeneca, sa
By a News Reporter-Staff News Editor at Clinical Trials Week BioClin Therapeutics, Inc., a clinical stage drug development company developing a first-in-class anti-FGFR3 monoclonal antibody for metastatic bladder cancer, announced expansion of its Series B financing to $50 million to broaden its clinical development activities.
By a News Reporter-Staff News Editor at Pharma Business Week Biohaven Pharmaceutical Holding Company Ltd. announced that it has established an expanded access program with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral sclerosis. Biohaven anticipates submitting a New Drug Application for BHV-0223 to.
By a News Reporter-Staff News Editor at Clinical Trials Week Biolex Therapeutics, Inc. announced that it has sold its LEX System, a proprietary platform for the development and production of biologics, to Synthon, a Netherlands- based specialty pharmaceutical company. Also included in the sale were two preclinical product candidates uniquely enab
Cantargia AB today announces that the United States Patent and Trademark Office has issued a Notice of Allowance for the company's patent application 15/ 501,710 directed to the antibody CAN03, which is of relevance for Cantargia's CANxx project.. Cantargia develops antibody based pharmaceuticals against the interleukin 1 receptor accessory prote
By a News Reporter-Staff News Editor at Clinical Trials Week A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal published a study in July 2011 reporting "risk of serious adverse cardiovascular events associated with varenicline." "We found no clinically or statistically.
By a News Reporter-Staff News Editor at Clinical Trials Week PITTSBURGH- Current research ethics focuses on protecting study participants, but according to bioethicists from Carnegie Mellon University and McGill University, these efforts fail to prevent problems that undermine the social value of research. Published in Science, CMU's Alex John Lo
By a News Reporter-Staff News Editor at Pharma Business Week Celsion Corporation, a leading oncology drug development company, announced that it has signed a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd., a leading pharmaceutical company in China, for the production of ThermoDox , Celsion's proprietary...
By a News Reporter-Staff News Editor at Pharma Business Week Pharmaceutical Product Development, LLC announced the appointment of Christopher Scully as executive vice president and chief financial officer. Scully most recently served at Pfizer, Inc. as chief commercial officer for the Pfizer essential health business unit. During his 21 years wit
Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online. By a News Reporter-Staff News Editor at Pharma Business Week Chugai Pharmaceutical Co., Ltd. announced that the long-term data from a global phase II study for nemoli
By a News Reporter-Staff News Editor at Clinical Trials Week Click Therapeutics, Inc., has been awarded a National Institutes of Health Small Business Innovation and Research grant through the National Institute of Drug Abuse. Clickotine will be compared head to head with the National Cancer Institute's smoking cessation app QuitGuide.
By a News Reporter-Staff News Editor at Pharma Business Week CStone Pharmaceuticals announced the successful completion of a $260 million financing, the largest Series B funding in the history of the China biopharmaceutical industry. The investment was led by GIC Private Limited, Singapore's sovereign wealth fund, with participation from new inve
By a News Reporter-Staff News Editor at Clinical Trials Week Daiichi Sankyo Company, Limited announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib met its primary endpoint of significantly prolonging overall survival compared to salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD
Data on Clinical Trials and Studies Detailed by Researchers at University of Ottawa. According to news reporting from Ottawa, Canada, by NewsRx journalists, research stated, "Rapid response teams are groups of health-care providers, implemented by hospitals to respond to distressed hospitalized patients on the hospital wards. The news correspondent
Using the U.S. Food and Drug Administration's Bioresearch Monitoring Information System database, we conducted an online survey to identify factors that affect principal investigators' decisions to conduct only a single FDA- regulated drug trial. " These same top three barriers also affected investigators' decisions to no longer conduct FDA- regula
The agreement also includes the license to Hisun of development and commercialization rights for Enzon's PEG-SN38, a novel, Phase II PEGylated version of SN38, in the territory of China. Once successfully PEGylated, Hisun will have the option to in-license the product candidates, based upon internal selection criteria, and will be fully responsible
By a News Reporter-Staff News Editor at Clinical Trials Week Exelixis, Inc. announced that IMblaze370, the phase 3 pivotal trial of atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, and cobimetinib, an Exelixis- discovered MEK inhibitor, did not meet its primary endpoint. Genentech, Exelixis'
FDA Grants Priority Review to Genentech's Cancer Immunotherapy TECENTRIQ Atezolizumab for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer. By a News Reporter-Staff News Editor at Cancer Vaccine Week Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company's...
According to news reporting out of Osaka, Japan, by NewsRx editors, research stated, "Imarikiren hydrochloride is a novel direct renin inhibitor. Financial support for this research came from Takeda Pharmaceutical Company. Our news journalists obtained a quote from the research from Takeda Pharmaceutical Company, "Subjects were randomized within 1
According to news reporting from Fujisawa, Japan, by NewsRx journalists, research stated, "Protein arginine methyltransferase 4 is involved in a variety of biological processes and is considered as a candidate oncogene owing to its overexpression in several types of cancer. Our news journalists report that additional information may be obtained by.
By a News Reporter-Staff News Editor at Clinical Trials Week BOSTON- A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis. These new findings, led by investigators at Beth Israel Deaconess Medical